- Medicines and Healthcare products Regulatory Agency
- 16 March 2017
- Last updated:
- 3 July 2017, see all updates
Download the full outcome
Detail of outcome
The Medicines and Healthcare products Regulatory Agency (MHRA) has agreed to reclassify Maloff Protect from a prescription only medicine (POM) to a Pharmacy (P) medicine in the UK for the prevention of malaria in adults weighing more than 40kg travelling to areas where malaria is widespread
See the public assessment report for more information.
Published: PDF, 400KB, 1 page
Published: PDF, 717KB, 2 pages
Published: PDF, 571KB, 2 pages
Published: PDF, 589KB, 3 pages
Published: PDF, 1.1MB, 1 page
Published: PDF, 877KB, 2 pages
Detail of feedback received
A total of 8 responses were received, of which 4 were in favour, 3 were not in favour and one was unsure. Two of the responses were confidential.
See all the responses to this consultation.
We are considering making Maloff Protect anti-malaria tablets available to buy from pharmacies. We always want to involve the public and healthcare professionals in decision that affect them. We want to know what you think about this change.
This consultation ran from
We want to know what you think
- Maloff Protect will be used in the prevention of malaria in adults travelling to areas where malaria is prevalent.
- Maloff, which contains the same active ingredients as Maloff Protect is only at the moment available on prescription.
- We propose to make Maloff Protect available in pharmacies.
- The MHRA considers that this product can be available as a Pharmacy medicine.
- We want to know what you think about this change.
Please tell us your views using the form at the end of the attached pdf.
The deadline for comments is 6 April 2017.
PDF, 1.68MB, 26 pages
MS Word Document, 30.5KB
MS Word Document, 1.19MB
Published: 16 March 2017
Updated: 3 July 2017
- RECLASSIFICATION GRANTED
- First published.